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Abstract
Objective: Electroporation mediated transfer of plasmid DNA into peripheral muscle results in high transfection efficiency. The aim of this
study was to investigate the effect of gene transfer of human IL-10 (hIL-10) into the tibialis anterior muscle (MTA) in combination with low dose
Cyclosporine A (CsA) on acute rejection of lung allografts in the rat. Methods: Lung allotransplantation was performed from male BN donor to
male Fisher F344 rats. Gene transfer was achieved by intramuscular injection into the MTA of the recipient followed by electroporation
(4!20 ms impulses at 200 V/cm) 24 h prior to the transplantation. Group A (nZ5) received CsA (2.5 mg/kg bw ip) for 5 days post-transplant and
group B (nZ5) 2.5 mg of PCIK hIL-10 (plasmid expression vector containing human CMV immediate early gene promoter and enhancer) and a low
dose CsA (2.5 mg/kg bw i.p.). Graft function was assessed by blood gas at day 5 after exclusion of the native lung. Animals were sacrificed and
blood was drawn to measure serum hIL-10 levels (ELISA) and tissue was sampled for histological grading of rejection. Results: Local expression
of hIL-10 was confirmed at the mRNA level by in situ hybridization. All group A control animals showed severe signs of rejection. At day 5 all
grafts in group B showed good gas exchange mean PaO2 233G123 mmHg, vs 44G8 mmHg in group A. Histological examination revealed
moderate to severe rejection in all animals in group A (IIIB, ISHLT) in contrast to low moderate rejection in group B (II–IIIA). hIL-10 serum levels
on day 5 were 14G7 pg/ml in group B vs. 0 in group A. Conclusions: Electroporation mediated hIL-10 overexpression in a peripheral muscle of
the recipient in combination with low dose CsA reduces acute rejection in this model of rat lung allotransplantation.
Q 2005 Elsevier B.V. All rights reserved.
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Allotransplantation of whole organs is an established
therapeutic option in end-stage disease. Much of the
progress in this field was made by the development and
improvement of immunosupressive agents such as Cyclos-
porine A (CsA), aziathioprine, tacrolimus, mycofenolate
mofetil, which are commonly used in the treatment of acute
rejection [1]. But still, administration of immunosupressive
agents such as CsA is associated with adverse effects and
high dosage of immunosupression in the initial phase after
transplantation increases the risk of infections [2].1010-7940/$ - see front matter Q 2005 Elsevier B.V. All rights reserved.
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immunomodulatory and anti inflammatory properties of
IL-10 ameliorates this reaction [3]. IL-10 is a pleiotropic
cytokine. It inhibits the synthesis of cytokines by TH1 cells
activated by monocyte/macrophage antigen-presenting
cells [4]. In addition it has been shown that IL-10 inhibits
monocyte/macrophage dependent T-cell activation and
antigen presentation [3,5], as well as alloreactivity
in vivo [6].
Gene transfer defined as the temporary introduction
of genes that results in transient gene expression and
production of a functional gene product to modify tissue
responses, might be an effective strategy to decrease
transplant rejection. Electroporation mediated gene trans-
fer to the skeletal muscle has evolved as a safe and efficient
method with very promising results [7]. The aim of this study
is to evaluate the effect of hIL-10 overexpression in
peripheral muscle tissue of the recipient in combination
with subtherapeutic doses of CsA to reduce acute rejection
in a fully mismatched orthotopic rat lung transplantation
model.European Journal of Cardio-thoracic Surgery 27 (2005) 1030–1035www.elsevier.com/locate/ejcts
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2.1. Plasmid
Plasmid pCik IL-10 was constructed by inserting hIL-10 c
DNA (537 bp) into a unique backbone of pCIk driven by
human CMV early promoter enhancer at Not K1 and Nhe 1
site [8] (Fig. 1). The plasmid was purified and produced in the
quantity required at (Plasmid Factory Gmbh &Co, Bielefeld
Germany).
2.2. Experimental groups
Left lung allotransplantation was performed in rats with
major full mismatch and one minor immunological mismatch
(Donor: Brown-Norway; Recipient: Fischer F344; obtained
from Harlan Netherlands B.V., Ad Horst, Netherlands). Two
groups (nZ5) were studied: Group A animals received sub
therapeutic doses of CsA 2.5 mg/kg/day i.p., starting the
day of transplantation. Group B (nZ5) received the same
dose of CsA per day in combination with transduction of
2.5 mg hIL-10, plasmid DNA (pCik hIL-10). In the second
group, pCiK hIL-10 was injected to the tibialis anterior
muscle followed by electroporation, 24 h prior to
transplantation.
CsA (Sandimmunw) was provided by Novartis Pharma AG,
Basel Switzerland and diluted in castor oil in a ratio of 1:9. All
animals received human care in compliance with the
‘Principles of Laboratory Animal Care’, formulated by the
National Society for Medical Research, and ‘Guide for the Care
and Use of Laboratory Animals prepared by the institute of
Laboratory Animal Research and published by the National
Institutes of Health (NIH Pub. No. 86-23, revised 1985)’. The
protocol was approved by the local animal study committee.
2.3. Operative procedure
2.3.1. Donor
The animal is anaesthetized in a glass chamber by inhaling
4% Halotane (SIGMA, Buchs, Switzerland). ThiopentalFig. 1. The plasmid expression vector pCiK IL-10 constructed by inserting
541 bp hIL-10 cDNA.(Pentotalw, Abbot AG, Baar, Switzerland) at a dosage of
50 mg/kg body weight (b.w.) is administered i.p. Heparine
(Liqueminw, Roche Pharma, Rheinach, Switzerland) is
administered by injection into the penile vein (500 IU/kg
b.w.). A trachostomy is performed and the animal is
ventilated with a 14 GA catheter (Insytew, Becto Dickinson,
Sandy UT USA) with 100% oxygen, a breathing frequency of
100/min, and tidal volume of 8 ml/kg body weight by a
rodent ventilator (Model 683, Harvard Apparatus, South
Natick MA USA). After cutting the inferior vena cava and left
appendix of the heart, a small silicon hose is inserted into
the main pulmonary artery (PA) via an incision in the right
ventricle. Both lungs are flushed with 20 ml of LPD solution
(Perfadexw,Vitrolife Pharmaceutics, Uppsala Sweden) at
20 cm H2O pressure. The trachea is then tied with the
lungs in end respiratory position. The heart-lung block is
removed and the left lung is separated ex vivo. Small plastic
cuffs are placed around the PA and the left pulmonary vein
(PV), the vessels are everted and tied on the cuffs and
fastened with 8–0 monofilament thread (Surgiprow, USSC,
Norwalk CT USA). The graft is stored in LPD solution at 10 8C
until implantation.2.3.2. Recipient
The recipient is anaesthetized by breathing 4% Halotane
in the glass chamber. Pentobarbital (Nembutalw, Abbot AG,
Baar Switzerland) at a dosage of 50 mg/kg is administered
i.p. Dissection of the left tibialis anterior muscle (MTA) is
performed. The muscle is injected with 2.5 mg of pCikhIL-10
with Omnican30 insulin syringe (Braun, Switzerland), and
subsequently placed between the plate electrodes.
4!20 ms impulses at 200 V/cm are applied with the INOVIO
Pulse Generator (Inovio Oslo).
After 24 h, the recipient is anaesthetized by breathing 4%
Halotane in the glass chamber again. Intubation is carried
out using a 14 GA catheter placed into the trachea.
Anaesthesia is maintained with Halotane at 2.5%. The
recipient is ventilated with 1 cm water PEEP, a breathing
frequency of 100/min and a tidal volume of 8 ml/kg body
weight by rodent ventilator. A left thoracotomy is per-
formed. The left hilum is dissected and micro clips are put on
the left pulmonary artery (PA) and the left pulmonary vein
(PV). The left main bronchus is ligated with 6–0 polyfilament
thread (Sofsilkw, USSC, Norwalk CT USA) and cut. An incision
is made in both PV and PA. The vessels are flushed with saline
solution. The cuffs of the donor lung are inserted into the
recipient’s vessels, and 6-0 polyfilament ligatures (Sofsilkw)
are placed around the cuffs and tied. The native PA and PV
are cut off beyond the anastomoses and the native lung is
removed. A 9-0 monofilament running over-and-over con-
tinuous suture (Monosofw, Tyco Healthcare, Wollerau
Switzerland) is employed for the bronchial anastomosis.
Ventilation is started. The microclips are removed to allow
retrograde and subsequently anterograde perfusion of the
graft. A small chest drain is inserted into the left pleural
space and the thoracotomy is closed with three layers of
continuous sutures. The chest drainage is removed
after spontaneous breathing is restored, followed by
extubation.
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For continuous data all values are given as meanGSD.
Data were log-transformed and the t-test performed on
these log-transformed data. A P-value less than 0.05 were
considered significant. The STATISTICA 5.1 software
(StatSoftw, Tulsa, OK) was used.3. Assessment
3.1. Graft function
Five days after the transplantation, the recipient is
preanaesthetized in a glass chamber inhaling 4% Halotane,
Thiopental (50 mg/kg bw) is administered i.p. The animal is
ventilated via a tracheostomy with the Harvard Rodent
Ventilator with FIO2Z1.0, a frequency of 100 breaths/min,
and a tidal volume of 8 ml/kg. A thoraco-laparotomy in the
anterior midline is done. Dissection of the right hilum is
performed. Microvascular clips are put on the right main
bronchus and right PA in order to ventilate and perfuse only
the isolated left lung graft. Five minutes after the occlusion,
1 ml of blood is aspirated from the aortic arch to a syringe
(Radiometer Pico 50, Copenhagen, Denmark) for blood gas
assessment (Radiometer ABL 700 Serie, Copenhgen, Den-
mark) and 1 ml of blood for the measurement of the serum
hIL-10 levels is collected from the inferior vena cava.
Subsequently, the inferior vena cava and left appendix of
the heart are incised and a small silicon hose is inserted into
the main PA via an incision in the right ventricle. The lungs
are then flushed with 20 ml of 0.9% saline solution under
pressure of 20 cm H2O. The heart-lung block is explanted
and tissue samples collected.
3.2. Histology
After explantation the graft is isolated and inflated to
total capacity with 4% formaline and placed in a container
with the same fixative for 12 h. After paraffin fixation the
sections were cut and routine haematoxylin and eosin
staining performed. The histological assessment was done
by a trained lung pathologist in blinded fashion according to
the Working Formulation for the Classification of Pulmonary
Allograft Rejection of the International Society for Heart and
Lung Transplantation [9].
3.3. hIL-10 expression
3.3.1. ELISA
Circulating serum levels of hIL-10 were measured using
hIL-10 immunoassay kit (R&D Systems, Abingdon UK)
following the manufacturers instructions. The antibody is
specific and no cross-reaction with rat IL-10 occurs. 1 ml
blood was drawn from the inferior vena cava on day 5 at
sacrifice, centrifuged, and stored at K20 8C till the
measurements. In order to assess the level of hIL-10 at the
time of transplantation two separate animals were injected
with pCikhIL-10 followed by electroporation as described
above, as the loss of 1 ml blood at the time of transplan-
tation results in a high mortality of the animals.3.3.2. In situ hybridization
The hIL-10 cDNA fragment (537 bp) was subcloned into
blue script vector (Stratagene, Europe The Netherlands).
The plasmid containing the cDNA probe inserts was linear-
ized using the restriction endonucleases Not-I for in vitro
transcription of the sense strand and HindIII for the antisense
strand. Single-stranded sense and antisense digoxigenin
(DIG)-labeled cRNA probes were transcribed in vitro using
1ug of linearized template and 40 units of the appropriate
polymerase (T7 RNA polymerase for the sense strand, SP6
RNA polymerase for the antisense strand) with DIG-labeled
uridine triphosphate (UTP) using the DIG RNA Labeling Kit
according to the manufacturer’s directions (Roche Diagnos-
tics, Basel Switzerland).
To localize the expression and distribution of hIL-10 after
in vivo electroporation in the skeletal muscle we performed
in situ hybridization to detect the expression at mRNA level.
Tissue sections were deparaffinized in a xylene series and
then rehydrated through a decreasing ethanol series diluted
in dimethyl pyrocarbonate-treated water. Sections were
then subjected to Proteinase K treatment at 37 8C for
10 min. After washing with 1XPBS sections were treated with
acetic anhydride for 10 min at room temperature. The slides
were washed again with 1XPBS and prehybridized for 2 h at
55 8C in the hybridization solution (Sigma/Aldrich USA) and
t-RNA before hybridization with 100 ng in 55 ul of the sense
or antisense cRNA DIG labelled probes in a humid chamber at
55 8C for 18 h. Hybridized slides were treated in increasingly
stringent pre-heated 2!SSCC50% formamide, 2!SSC, 0.2%
SDS for 15 min at 37 8C, followed by two washes with
0.1!SSC, 0.2% SDS for 15 min at 60 8C. Detection was carried
out by incubation with an alkaline phosphatase conjugated
anti-DIG antibody using nitroblue tetrazolium chloride and
5-bromo-4-chloro-3-indolyl phosphate according to the
manufacturer’s instructions (Roche Diagnostics, Basel
Switzerland).4. Results
4.1. Characterisation of experimental groups
Donors and recipients weighed 220–240 g, 240G20 g with
no statistical difference between groups. The transplan-
tation procedure was performed within a mean 180G15 min.
Warm ischemic time was 30G5 min, without statistical
differences between groups.
4.2. Graft function
PaO2 (meanGSD) levels in arterial blood, obtained 5 min
after right hilar crossclamping in group B (233G123 mmHg)
were significantly higher than those in group A (44G
8 mmHg) (PZ0.0091).
4.3. Rejection grading
The histopathological assessment demonstrated improve-
ment in lung architecture in the treated animals as seen by
the rejection score of II–III A in group B (Fig. 2) as compared
to III B in group A (Fig. 3, Table 1).
Fig. 2. The transplanted lung of treated animals (group B) shows mostly clear
alveoli. The perivascular and the peribronchiolar infiltrate (arrow) is still
visible at low magnification, but it is clearly less dense and the alveolar
epithelium is unchanged (inset). (Hematoxylin&eosin, bar 100 mm, inset
50 mm).
Table 1
Low dose CsA hIL-10CCsA
Vascular A3 (A2–A3) A2 (A2–A3)
Airway B3 (B2–B3) B2 (B2–B3)
Histological assessment of the grafts for rejection scoring using the ISHLT
formulation was implied. Although the difference is not significant yet is
considerable since the functional parameters as the PaO2 shows significant
improvement.
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Sustained levels of human IL-10 in the circulation of pCik
hIL-10 transfected rats were detected. Serum levels of
hIL-10 increased significantly after electroporation
mediated hIL-10 transfection 74G4 pg/ml at 24 h and
14G7 pg/ml at day 5, in group B. No hIL-10 was detected
in the serum of group A animals at either time point (Fig. 4).
4.5. Local expression of hIL-10 in the tibialis anterior muscle
The expression, histologic localization, and the persist-
ence of hIL-10 in the transduced muscle was determined byFig. 3. A representative histological section of the graft of group A, at day 5.
The dense infiltrate around the pulmonary blood vessels and the bronchioles is
visible at low magnification. Moderately increased macrophages and a faint
edema occupy the alveoli. Inset: high magnification reveals up to five layers of
a lymphocytic infiltrate (arrow) around a pulmomary vein. Note the increased
number of endothelial cells. The infiltrate reaches focally the alveolar
interstitium (arrowhead). The alveolar epithelial cells are increased in
number. Histological assessment revealed low moderate rejection in group
B II–IIIA (Fig. 2). In contrast to moderate to severe rejection in all animals in
group A IIIB–IV (Fig. 3).in situ hybridization. An antisense probe to hIL-10 detected
transcripts in muscle fibers and in macrophages. The sense
probe showed no signal, indicating the specificity of the
signal for hIL-10 (Fig. 5).5. Discussion
The present study demonstrates a synergistic effect of
hIL-10 overexpression and sub therapeutic doses of Cyclos-
porine A (CsA). The treated animals showed improved graft
function and reduced histologic rejection on day 5 post-
transplantation in this model of lung allotransplantation.
The idea to reduce the alloimmune response after organ
transplantation by overexpression of immunosuppressive
proteins has been pursued by a number of groups [10,11],
however, the technique so far was limited, first by the low
efficiency of gene transfer, and second by temporary
expression of the transgene. Previous studies evaluated
the effect on acute rejection by local expression of
transgene in the graft [11]. This may be more effective if
only a low expression is desired. In addition, if the
transduction is done at the time of organ harvest, in vivo
or ex vivo, it is difficult to get a homogenous expression in
the graft tissue which might limit the effect substantially. On
the other hand the graft might be damaged by the
transduction itself, as viral vectors cause inflammatory
responses and the most effective non viral vectors, as for
example PEI, are rather toxic for the lungs [12]. In contrast,
peripheral transduction in the muscle results in high
expression of the transgene in the recipient and is
technically easy to achieve.Fig. 4. hIL-10 expression and localization Levels of circulating hIL-10 in the
serum of the rat at day 1 (74G4 pg/ml) and at day 5 after electroporation
mediated gene transfer (14G7 pg/ml) (meanGSD). The hIL-10 levels in rat
control serum was 0.
Fig. 5. mRNA expression and localization in the myocytes and macrophages in
the M. tibialis anterior of a group B animal by in situ hybridization. Inset
(Negative control sense probe).
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promising gene delivery method. The technique is not only
available at low cost, but its easiness of application in
addition to its safety of production of the plasmid constructs
are unique. Several reports show that it is one of the most
efficient non-viral strategies [7], increasing reporter gene
and therapeutic gene expression by several orders of
magnitude over conventional non viral and viral vectors
(Gazdhar et al, in press). In vivo electroporation is a physical
method of gene transfer. The plasmid DNA is injected
followed by delivery of a series of electric pulses of short
duration using suitable electrodes. In preliminary studies we
observed hIL-10 transduction alone was not consistently
effective in reducing the acute rejection in lung transplan-
tation model in spite of high hIL-10 serum levels.
IL-10 is a potent suppressor of TNFa Interleukin-1b,
interleukin-6, interleukin-12, and interferong production
and may facilitate the induction of tolerance after allogenic
transplantation [13,14]. Both CsA and IL-10 act synergisti-
cally inhibiting T cell activation and IL-2 and TNFa
production. CsA inhibits calcineurin; IL-10 inhibits both Th1
cell proliferation and other proinflammatory cytokines.
Thus, each drug acts via an independent pathway yet exert
a complimentary immunosuppressive effect, but timing of
gene transfer and the route of administration may play a key
role. Our preliminary data showed that IL-10 overexpression
at the time or after transplantation had little effect or was
even detrimental, as reported earlier by other groups
[15–17]. In contrast previous reports show that IL-10
treatment of the recipient prior to transplantation enhances
graft survival of heart allografts in mice [18], and rat liver
allografts [19], and was effective in studies of bone marrow
transplantation [20]. Very high doses of IL-10 have also
proved to be deleterious as reported earlier [16], hence the
optimal dosage is crucial.
In a study by Itano et al. the use of lipid mediated viral
IL-10 transduction to the lung graft reduced rejection [21].
In our study hIL-10 was used which is active in the rat due to
receptor homology [22,23] and which also results in higher
serum concentrations than viral IL-10 as latter has beenshown to be retained in the tissue compartments [24]. The
sustained levels of circulating hIL-10 in the blood in the
present experiments highlights the possibility to use the
muscle for secretion of proteins into circulation thus opening
a large field of therapeutic options [25].
In summary, our observations support the key role of IL-10
during the initial events of lung transplantation. The time
course of the hIL-10 serum levels in the present experiment
shows peak levels at 24 h, gradually decreasing over the next
five days. This fast increase of circulating hIL-10 achieved
with the CMV promoter seems to be ideal for the prevention
of acute rejection, however; other constructs that are
currently evaluated by our group have to be employed for
the maintenance of the transgene expression over longer
time (Gazdhar et al. in press). In a parallel study conducted
by our group, (Tavakoli et al in press) it has been shown that
in cardiac transplantation hIL-10 alone, without additional
CsA, is effective to reduce acute rejection in the same strain
combination. In renal allografts, however, IL-10 has a
detrimental effect [3].
In conclusion, we have demonstrated that electropora-
tion mediated gene transfer of hIL-10 to skeletal muscle of
the recipient in combination with low dose CsA improves
lung allograft function, and reduces histologic rejection.
This approach may even have clinical potential, as the
method is easily applicable and may help to modify current
methods of immunosupression in the early phase after
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Dr N. Daddi (Perugia, Italy): I have mainly two questions to ask you. The
first one is about the method. When you transfect the muscle with
electroporation, did you also check the Human IL-10 concentration in both
lungs and in other organs as heart, liver and kidney?
The second question is on the gene you adopted. The molecular structure
of Human IL-10 is similar to cellular IL-10 produced in the animal. The anti-
inflammatory activity of cellular IL-10 is known by downregulating several
pro-inflammatory cytokines and natural killer cell activity. Conversely, this
potent anti-inflammatory cytokine might have an important role in the
differentiation of mastocytes.
Did you consider other gene vectors as a plasmid encoding viral IL-10? This
cytokine is structurally similar to cellular IL-10. It inhibits as well the activity
of the cytokines and downregulates the expression of major histocompat-
ibility complex II on the surface of monocytes but does not possess the
costimulatory effect on mastocytes.
Dr Pierog: We measured overexpression of human IL-10 only in the
electroporated muscle and in circulating blood. We didn’t measure the
expression in the lung or in the liver. The human IL-10 was distributed to
the bloodstream systematically. Regarding to your second question, we
decided to use only human interleukin-10 because it results in higher serum
concentration and makes it available systematically, whereas viral IL-10, is
retained in the tissue compartments.
Dr D. Van Raemdonck (Leuven, Belgium): You’ve shown a nice drop in
serum levels of interleukin-10 from post transplant day 1 to day 5. Can you
also give us the figure on the level pre transplantation. Was there an increase
in interleukin-10?
Dr Pierog: This expression was according to the CMV promoter/enhancer
included in the plasmid. This promoter allows high expression which occurs
24 hours following gene transfer, the levels were measured before transplan-
tation, and then the expression gradually decreases between day 1 and day 5.
This pattern of the expression was confirmed also in other experiments
performed in our laboratories.
Dr G. Laufer (Innsbruck, Austria): You’re basically augmenting your
immunosuppression by this immunosuppressive cytokine. What would be the
consequences for infection? I mean, if you have high levels of IL-10, that might
also impair the resistance to viral infection, susceptibility to viral infection
and viral disease early after transplantation.
Dr Pierog: We didn’t assess susceptibility for infection. I can say that I
performed many lung transplantations with using this regimen of immuno-
suppression and I have not seen any infections during the post operative
course because the recipients were sacrificed after 5 days.
Dr D. Van Raemdonck (Leuven, Belgium): My final question would be, you
did this gene transfer 24 hours prior to transplantation, how would you
translate it to the clinical practice? How do we know 24 hours in advance that
there will be a donor?
Dr Pierog: In the literature it has been demonstrated that human
interleukin-10 administered after lung transplantation had no beneficial
effect on lung transplantation. Even the rejection score may be worse after
administration of human interleukin-10 following lung transplantation. In
contrast, administration of human interleukin-10 prior to implantation has a
beneficial effect. The mechanism of this phenomenon has not been elucidated
so far.
Dr Van Raemdonck: But 24 hours seems a long period in advance. Have
you looked at 12 or 6 hours prior to transplant?
Dr Pierog: This is an experimental setting for a proof of principle. The
recipients were electroporated 24 hours prior to implantation because of the
expression pattern provided by the CMV promoter of the plasmid, and because
it is known that the levels of pro inflammatory cytokines like IL-2 and INFg
attain the peak between 6 to 12 hours after transplantation, hence in order to
achieve high expression of human IL-10 in the bloodstream at this time point a
24-hour interval might be ideal.
